Skip to main content

John Yates, Lester Crawford, and Mark McClellan

John Yates has been named to the scientific advisory board of Protein Discovery, the company said this week. Yates is a professor of cell biology and the principal investigator of the Proteomic Mass Spectrometry Laboratory at the Scripps Research Institute.

Former US Food and Drug Administration Commissioner Lester Crawford pleaded guilty this week to charges by the US Department of Justice for lying about stock he held while he headed the agency and for conflict of interest.
Each charge carries a maximum penalty of one year in jail.
The DOJ alleged Crawford had said he sold stocks in companies that he and his wife owned that were regulated by the FDA while he was a deputy commissioner at the FDA when, in fact, he had not. Those companies include Sysco, Wal-Mart, and Kimberly-Clark.
Relating to the conflict-of-interest charges, the DOJ said that during a period when he headed the FDA Obesity Working Group,which among other things was looking into calorie content labeling for soft drinks, Crawford held more than $60,000 in shares of Pepsico and $78,000 in shares of Sysco, a food distribution company.
Crawford was also accused of failing to report about $28,000 in income he made from the sale of shares in Embrex while he held a leadership position at the FDA. Embrex is an agricultural biotech company regulated by the FDA.
Crawford headed the FDA for two months before resigning abruptly in September 2005 without stating a reason. He had been the acting head of the agency for more than a year. He is now a senior staff member of Washington DC lobbying firm Policy Directions.


Former FDA Commissioner Mark McClellan, who until Saturday was administrator of the Center for Medicare and Medicaid Services,has joined the AEI-Brookings Joint Center for Regulatory Studies think tankas a visiting senior fellow. He will be working on developing and implementing ideas to improve health care quality.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.